These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

924 related articles for article (PubMed ID: 11159700)

  • 41. Discovery of a novel class of potent coumarin monoamine oxidase B inhibitors: development and biopharmacological profiling of 7-[(3-chlorobenzyl)oxy]-4-[(methylamino)methyl]-2H-chromen-2-one methanesulfonate (NW-1772) as a highly potent, selective, reversible, and orally active monoamine oxidase B inhibitor.
    Pisani L; Muncipinto G; Miscioscia TF; Nicolotti O; Leonetti F; Catto M; Caccia C; Salvati P; Soto-Otero R; Mendez-Alvarez E; Passeleu C; Carotti A
    J Med Chem; 2009 Nov; 52(21):6685-706. PubMed ID: 19810674
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Selective inhibition of monoamine oxidase A or B reduces striatal oxidative stress in rats with partial depletion of the nigro-striatal dopaminergic pathway.
    Aluf Y; Vaya J; Khatib S; Loboda Y; Finberg JP
    Neuropharmacology; 2013 Feb; 65():48-57. PubMed ID: 22982254
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Selegiline and rasagiline: twins or distant cousins?
    Knudsen Gerber DS
    Consult Pharm; 2011 Jan; 26(1):48-51. PubMed ID: 21224199
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical pharmacology of rasagiline: a novel, second-generation propargylamine for the treatment of Parkinson disease.
    Chen JJ; Swope DM
    J Clin Pharmacol; 2005 Aug; 45(8):878-94. PubMed ID: 16027398
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Novel bifunctional drugs targeting monoamine oxidase inhibition and iron chelation as an approach to neuroprotection in Parkinson's disease and other neurodegenerative diseases.
    Youdim MB; Fridkin M; Zheng H
    J Neural Transm (Vienna); 2004 Oct; 111(10-11):1455-71. PubMed ID: 15480846
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effects of rasagiline, its metabolite aminoindan and selegiline on glutamate receptor mediated signalling in the rat hippocampus slice in vitro.
    Dimpfel W; Hoffmann JA
    BMC Pharmacol; 2011 Feb; 11():2. PubMed ID: 21338509
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Possible mechanism of selective inhibition of rat liver mitochondrial monoamine oxidase by chlorgiline and deprenyl].
    Severina IS
    Biokhimiia; 1979 Feb; 44(2):195-207. PubMed ID: 435561
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Lipophilicity plays a major role in modulating the inhibition of monoamine oxidase B by 7-substituted coumarins.
    Carotti A; Altomare C; Catto M; Gnerre C; Summo L; De Marco A; Rose S; Jenner P; Testa B
    Chem Biodivers; 2006 Feb; 3(2):134-49. PubMed ID: 17193252
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Rasagiline, a suicide inhibitor of monoamine oxidases, binds reversibly to α-synuclein.
    Kakish J; Tavassoly O; Lee JS
    ACS Chem Neurosci; 2015 Feb; 6(2):347-55. PubMed ID: 25514361
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Binding of rasagiline-related inhibitors to human monoamine oxidases: a kinetic and crystallographic analysis.
    Binda C; Hubálek F; Li M; Herzig Y; Sterling J; Edmondson DE; Mattevi A
    J Med Chem; 2005 Dec; 48(26):8148-54. PubMed ID: 16366596
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Molecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug TV3326 [(N-propargyl-(3R)aminoindan-5-YL)-ethyl methyl carbamate].
    Youdim MB; Weinstock M
    Cell Mol Neurobiol; 2001 Dec; 21(6):555-73. PubMed ID: 12043833
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Rasagiline, an inhibitor of MAO-B, decreases colonic motility through elevating colonic dopamine content.
    Liu CZ; Zhang XL; Zhou L; Wang T; Quan ZS; Zhang Y; Li J; Li GW; Zheng LF; Li LS; Zhu JX
    Neurogastroenterol Motil; 2018 Nov; 30(11):e13390. PubMed ID: 29956417
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion.
    Gal S; Zheng H; Fridkin M; Youdim MB
    J Neurochem; 2005 Oct; 95(1):79-88. PubMed ID: 16181414
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Species-dependent differences in monoamine oxidase A and B-catalyzed oxidation of various C4 substituted 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridinyl derivatives.
    Inoue H; Castagnoli K; Van Der Schyf C; Mabic S; Igarashi K; Castagnoli N
    J Pharmacol Exp Ther; 1999 Nov; 291(2):856-64. PubMed ID: 10525109
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Effect of a new antiparkinsonian drug himantane on monoamine oxidase activity].
    Val'dman EA; Voronina TA; Aksenova LN; Buneeva OA; Medvedev AE
    Eksp Klin Farmakol; 2003; 66(5):3-5. PubMed ID: 14650204
    [TBL] [Abstract][Full Text] [Related]  

  • 56. TV3326, a novel neuroprotective drug with cholinesterase and monoamine oxidase inhibitory activities for the treatment of Alzheimer's disease.
    Weinstock M; Bejar C; Wang RH; Poltyrev T; Gross A; Finberg JP; Youdim MB
    J Neural Transm Suppl; 2000; (60):157-69. PubMed ID: 11205137
    [TBL] [Abstract][Full Text] [Related]  

  • 57. L-methamphetamine and selective MAO inhibitors decrease morphine-reinforced and non-reinforced behavior in rats; Insights towards selegiline's mechanism of action.
    He S; Grasing K
    Pharmacol Biochem Behav; 2006 Dec; 85(4):675-88. PubMed ID: 17157368
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Increased striatal dopamine production from L-DOPA following selective inhibition of monoamine oxidase B by R(+)-N-propargyl-1-aminoindan (rasagiline) in the monkey.
    Finberg JP; Wang J; Bankiewicz K; Harvey-White J; Kopin IJ; Goldstein DS
    J Neural Transm Suppl; 1998; 52():279-85. PubMed ID: 9564628
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Potentiation of para-hydroxyamphetamine-induced head-twitch response by inhibition of monoamine oxidase type A in the brain.
    Tadano T; Satoh S; Satoh N; Kisara K; Arai Y; Kim SK; Kinemuchi H
    J Pharmacol Exp Ther; 1989 Jul; 250(1):254-60. PubMed ID: 2501477
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases: in vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition.
    Zheng H; Gal S; Weiner LM; Bar-Am O; Warshawsky A; Fridkin M; Youdim MB
    J Neurochem; 2005 Oct; 95(1):68-78. PubMed ID: 16181413
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 47.